Sitravatinib

Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib is being developed by Mirati Therapeutics. Ongoing phase II trials include a trial for liposcarcoma, a combination trial for non-small cell lung cancer, and a combination trial with nivolumab for renal cell carcinoma.